Recombinant lubricin

Drug Profile

Recombinant lubricin

Alternative Names: ECF 843; lubricin recombinant; rh-lubricin

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lubris BioPharma
  • Developer Dompe Farmaceutici; Lubris BioPharma
  • Class Eye disorder therapies; Glycoproteins; Recombinant proteins
  • Mechanism of Action Glycoprotein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry eyes
  • Preclinical Osteoarthritis

Most Recent Events

  • 26 Jan 2017 Dompé Farmaceutici plans a pre-market study for Dry eyes in Italy (Ophthalmic, Drops) (NCT03031327)
  • 20 Sep 2016 Efficacy data from a Clinical trial in Dry eyes released by Lubris Biopharma (NCT02510235)
  • 25 Jul 2016 Preclinical trials in Dry eyes in USA before July 2016(unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top